The Cologne shareholders will be behind the security upgrade: former partners

August 2, in order to protect an ordinary general meeting of shareholders, the Cologne pharmaceutical industry (002422, shares bar) (closing price of 56.01 yuan) not only changed the venue, but also greatly enhanced the security forces in the venue. It all stems from a feud between the drug industry and former partners. Shareholders will be required to enter security clearance July 17, the Cologne issued a notice announced the site meeting venue: Chengdu, a ring Road West section 119th Chengdu Millennium Hotel Conference room. This is also the common place for the holding of the general meeting of the pharmaceutical industry. The subject of the meeting was to consider the motion on increasing the financing of the Company and its subordinate (sub) companies by the Sichuan Cologne Pharmaceutical Co., Ltd. However, only six days later, the Cologne pharmaceutical industry suddenly changed its venue to the Crowne Plaza Chengdu Poly Park Hotel in Xindou District. On the morning of August 2, when the daily economic news reporter arrived at the meeting, it was a surprise to see the security scene. Around 8:30, two rows of security officers were standing on the corridor outside the hall, with dozens of people. After registering personal information, security personnel to the reporter security, the process is like the airport as strict. When the reporter entered the venue found that the two sides of the venue are also neatly standing with a number of security personnel, the venue appears serious and tense. Around nine o'clock in the morning, the meeting officially began, surrounded by security personnel, including the chairman of the Liu Genue of the Cologne pharmaceutical industry executives admission, the number of security personnel will not leave Liu reform around. One insider told the Daily Economic news reporter that such stringent security measures were designed to ensure the smooth conduct of the meeting. Partners Huff and the drug industry shareholders will be so ready, or with the company and the former partner Chengdu, the feud between the enmity. The material of the Cologne pharmaceutical industry shows that September 2010 mid-June, Chengdu, the actual control of the Liu Genue by the middleman to find the country, claiming that its in Xinjiang Yili has the construction of erythromycin, such as antibiotics intermediates resources, referral to the drug industry to Xinjiang Yili Investment in the project, and hope to jointly build with the Cologne pharmaceutical industry. But the two sides to Xinjiang yili actual investigation and set up Xinjiang Cologne Biological Technology Co., Ltd. (hereinafter referred to as Xinjiang Cologne) five days after the Deiyun because involved in a case by the relevant departments to take coercive measures, leading to the early termination of this cooperation of the pharmaceutical industry. In response to the dispute, Xiang, the pharmaceutical secretary, said at the shareholder meeting that the company did have the cooperation agreement with the Chengdu Jiawei. The main content is the common investment in Xinjiang to establish antibiotic intermediates project. At the invitation of Chengdu Jiawei, the company visited Xinjiang in September 2010. In 2010 in October, the two sides jointly funded the establishment of the Xinjiang Cologne. Xiang said that at that time, when the Chengdu victory was almost paralyzed, if the company continued to insist on investment in Xinjiang, it is extremely irresponsible to listed companies and investors, so in order to control the risk, the Cologne pharmaceutical industry initiated the relevant legal procedures to terminate and remove the cooperation with the Chengdu Jiawei. As a result of buying the shares of the Cologne pharmaceutical industry, the son of Yun Kingdom came to attend the meeting as a shareholder. On the afternoon of August 4, Dai, nephew of Cloud country, to the dailyEconomic news reporter said, "Cologne is a great company, Liu Innovation is also a respectable entrepreneur", but good entrepreneurs should follow the spirit of contract and credit standards. Chengdu, it is hoped that the branch LUN pharmaceutical industry strictly enforce the agreement signed by both parties. Now that we have signed an agreement, we should share the risks and benefits. Dai said he followed Uncle Deiyun in the erythromycin industry for more than 10 years, the industry is very understanding. In his opinion, the location of erythromycin project in Xinjiang is very advantageous, one is rich in Xinjiang coal resources, the other is superior natural condition in Yili Valley, which is suitable for the production of erythromycin. The project was built with a handful of global capacity and a huge cost advantage. Project dispute the Bureau of the annual report on the drug industry, October 21, 2010, the company used its own capital of 51 million yuan and Chengdu, the joint establishment of Xinjiang Cologne. The company registered capital of 100 million yuan, main bio-energy and biochemical industry investment. The company holds a 51% per cent stake in the firm. It is noteworthy that, December 10, 2010, the Cologne pharmaceutical industry also uses its own funds 8.5 million yuan and two natural persons jointly invested in the establishment of Sichuan-Nanjing Company, the Cologne pharmaceutical industry holds a 85% stake. Since then, the Cologne pharmaceutical industry through the Sichuan-Nanjing company invested heavily into the field of erythromycin thiocyanate. 2011, the Cologne pharmaceutical industry announced an investment of 4 billion yuan in Yili, Xinjiang, the establishment of "million tons of antibiotic intermediates project." Last year, the first phase of the project was successfully tested by erythromycin thiocyanate Pilot Plant. Public reports say the 62-year-old Liu Genue himself Tong the large volume of the project. In the past two years, Liu Innovation rarely return to Sichuan headquarters, he most of the time "bubble" in the Xinjiang site. In the shareholder meeting, Liu Genue Frankly, Xinjiang project is as the company to start the whole industrial chain of antibiotics core hub, the key to the Life-and-death. Chengdu, the victory of the pharmaceutical industry, the Cologne contract and the new establishment of Sichuan-Nanjing company engaged in the same product production, seriously violated the interests of the partners. In this respect, Liu Genue said that Cologne will use legal means to resolve the dispute. It is reported that as early as 2011, the Cologne pharmaceutical industry to the Chengdu Intermediate People's Court to sue Chengdu, to confirm the lifting of the "investment Agreement" and the supplementary agreement, and return to the Cologne pharmaceutical industry 44 million yuan. "We have been communicating, hoping to properly resolve, to achieve both sides satisfactory results." But there are big differences between the two sides, especially in the allocation of shares. "Dai said. In the communication with reporters, Dai repeatedly said that this matter is very complex. Litigation disputes are not expected to be resolved in a short period of time.